Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Douglas F., Tobias, Hillel, Min, Albert D., Rajendra, Arathi, Zic, Ivanka, Brettholz, Edward, Clain, David J., Klion, Franklin, Bernstein, David, Bodenheimer, Henry C.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://www.ncbi.nlm.nih.gov/pubmed/21188197
http://dx.doi.org/10.1155/2010/537827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/
https://www.ncbi.nlm.nih.gov/pubmed/21188197
http://dx.doi.org/10.1155/2010/537827

Ejemplares similares